Research map: SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1–High, Locally Advanced, Unresectable or Metastatic Non–Small Cell Lung Cancer

Back to the article

Papers in this map

  1. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients · Roy S. Herbst · 2014 · 5363 citations · Cited by this paper
  2. Mechanisms of Resistance to Immune Checkpoint Inhibitors and Therapeutic Strategies to Overcome Them: An Integrative Review · Ehsan Lotfi · 2026 · Cites this paper
  3. Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab · 2026 · Related
  4. The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function · Robert J. Johnston · 2014 · 1206 citations · Cited by this paper
  5. SKYSCRAPER-07: Falling Short of the Top · S.S. Kim · 2026 · Cites this paper
  6. Virtual Sustained Tobacco Treatment for Patients With Cancer: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) Within the National Cancer Institute Community Oncology Research Program · 2026 · Related
  7. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study · Byoung Chul Cho · 2022 · 461 citations · Cited by this paper
  8. Innovate or Be Left Behind: A Path to Prospective External Control Arms for Accelerated Oncology Drug Development · 2026 · Related
  9. TIGIT: A Key Inhibitor of the Cancer Immunity Cycle · Nicholas A. Manieri · 2016 · 428 citations · Cited by this paper
  10. AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group · 2026 · Related
  11. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study · Gilberto de Castro · 2022 · 345 citations · Cited by this paper
  12. Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up · 2026 · Related
  13. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study · Michael Joseph Boyer · 2021 · 261 citations · Cited by this paper
  14. Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor · 2026 · Related
  15. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy · Eugene Y. Chiang · 2022 · 236 citations · Cited by this paper
  16. Moderate Hypofractionation for Regional Node Irradiation Is Safe and Effective · 2026 · Related
  17. Anti-TIGIT therapies for solid tumors: a systematic review · Adrien Rousseau · 2023 · 157 citations · Cited by this paper
  18. Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743 · 2026 · Related
  19. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells · Xiangnan Guan · 2024 · 147 citations · Cited by this paper
  20. Limiting Dexamethasone Exposure With Highly Emetogenic Chemotherapy Regimens: Is the Verdict In? · 2026 · Related
  21. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial · Byoung Chul Cho · 2023 · 95 citations · Cited by this paper
  22. Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update · 2026 · Related
  23. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors · Tae Won Kim · 2023 · 73 citations · Cited by this paper
  24. Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study · Richard S. Finn · 2025 · 68 citations · Cited by this paper
  25. Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype · Stefanie Hiltbrunner · 2023 · 66 citations · Cited by this paper
  26. TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation · Jonathan D. Worboys · 2023 · 60 citations · Cited by this paper
  27. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3 · Natasha B. Leighl · 2025 · 19 citations · Cited by this paper
  28. Updated treatment recommendations for systemic treatment: from the ESMO non-oncogene-addicted metastatic NSCLC Living Guideline · Lizza E.L. Hendriks · 2025 · 19 citations · Cited by this paper
  29. OA11.03 Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific, for CPI-naïve Metastatic NSCLC with PD-L1 1-49% or ≥50% · T.J.N. Hiltermann · 2024 · 18 citations · Cited by this paper
  30. STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non–Small Cell Lung Cancer With No Actionable Gene Alterations · Delvys Rodríguez‐Abreu · 2024 · 15 citations · Cited by this paper
  31. LBA52 Interim analysis of GALAXIES Lung-201: Phase II, randomized, open-label platform study of belrestotug plus dostarlimab in patients (pts) with previously untreated locally advanced/metastatic (LA/M) PD-L1 high (TPS >/=50%) non-small cell lung cancer (NSCLC) · D.R. Spigel · 2024 · 12 citations · Cited by this paper
  32. LBA2 SKYSCRAPER-06: Efficacy and safety of tiragolumab plus atezolizumab plus chemotherapy (tira + atezo + chemo) vs pembrolizumab plus chemotherapy (pembro + chemo) in patients (pts) with advanced non-squamous non-small cell lung cancer (NSq NSCLC) · M.A. Socinski · 2024 · 8 citations · Cited by this paper
  33. Untitled · Cited by this paper
  34. Untitled · Cited by this paper
  35. Untitled · Cited by this paper
  36. Untitled · Cited by this paper

Source: OpenAlex (CC0)